Toll-like receptor signaling pathways and the evidence linking toll-like receptor signaling to cardiac ischemia/reperfusion injury

Shock

Volumn 34, Issue 6, 2010, Pages 548-557

  Wang, Yue ^a   Abarbanell, Aaron M ^a   Herrmann, Jeremy L ^a   Weil, Brent R ^a   Poynter, Jeffrey ^a   Manukyan, Mariuxi C ^a   Crisostomo, Paul R ^a   Meldrum, Daniel R ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

ischemia reperfusion injury; signaling pathways; Toll like receptor

Indexed keywords

BETA INTERFERON; GAMMA INTERFERON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE 1; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE 2; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE 4; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 6; INTERLEUKIN 8; MYELOID DIFFERENTIATION FACTOR 88; PHOSPHATIDYLINOSITOL 3 KINASE; SELECTIVE ANDROGEN RECEPTOR MODULATOR; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 1; TOLL LIKE RECEPTOR 11; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 6; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8; TOLL LIKE RECEPTOR 9; TOLL LIKE RECEPTOR ADAPTOR MOLECULE 1; TOLL LIKE RECEPTOR ADAPTOR MOLECULE 2; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6; UNINDEXED DRUG;

CYTOKINE PRODUCTION; HEART MUSCLE INJURY; HEART MUSCLE ISCHEMIA; IMMUNOREGULATION; INNATE IMMUNITY; KNOCKOUT MOUSE; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PROTEIN PROTEIN INTERACTION; REPERFUSION INJURY; REVIEW;

ANIMALS; HUMANS; MODELS, BIOLOGICAL; REPERFUSION INJURY; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTORS;

EID: 78649636498     PISSN: 10732322     EISSN: None     Source Type: Journal    
DOI: 10.1097/SHK.0b013e3181e686f5     Document Type: Review

References (141)

1. Frantz S, Ertl G, Bauersachs J: Mechanisms of disease: Toll-like receptors in cardiovascular disease. Nat Clin Pract Cardiovasc Med 4:444-454, 2007.
2. Frantz S, Kobzik L, Kim YD, Fukazawa R, Medzhitov R, Lee RT, Kelly RA: Toll4 (TLR4) expression in cardiac myocytes in normal and failing myocardium. J Clin Invest 104:271-280, 1999.
3. Okamura Y, Watari M, Jerud ES, Young DW, Ishizaka ST, Rose J, Chow JC, Strauss JF 3rd: The extra domain A of fibronectin activates Toll-like receptor 4. J Biol Chem 276:10229-10233, 2001.
4. Cohen-Sfady M, Nussbaum G, Pevsner-Fischer M, Mor F, Carmi P, Zanin-Zhorov A, Lider O, Cohen IR: Heat shock protein 60 activates B cells via the TLR4-MyD88 pathway. J Immunol 175:3594-3602, 2005.
5. Kagan JC, Su T, Horng T, Chow A, Akira S, Medzhitov R: TRAM couples endocytosis of Toll-like receptor 4 to the induction of interferon-beta. Nat Immunol 9:361-368, 2008.
6. Lund JM, Alexopoulou L, Sato A, Karow M, Adams NC, Gale NW, Iwasaki A,Flavell RA: Recognition of single-stranded RNA viruses by Tolllike receptor 7. Proc Natl Acad Sci USA 101:5598-5603, 2004.
7. Takeda K, Kaisho T, Akira S: Toll-like receptors. Annu Rev Immunol 21:335-376, 2003.
8. Pevsner-Fischer M, Morad V, Cohen-Sfady M, Rousso-Noori L, Zanin-Zhorov A, Cohen S, Cohen IR, Zipori D: Toll-like receptors and their ligands control mesenchymal stem cell functions. Blood 109:1422-1432, 2007.
9. Chuang T, Ulevitch RJ: Identification of hTLR10: a novel human Toll-like receptor preferentially expressed in immune cells. Biochim Biophys Acta 1518:157-161, 2001.
10. Matsumoto M, Funami K, Tanabe M, Oshiumi H, Shingai M, Seto Y, Yamamoto A, Seya T: Subcellular localization of Toll-like receptor 3 in human dendritic cells. J Immunol 171:3154-3162, 2003.
11. Ahmad-Nejad P, Hacker H, Rutz M, Bauer S, Vabulas RM, Wagner H: Bacterial CpG-DNA and lipopolysaccharides activate Toll-like receptors at distinct cellular compartments. Eur J Immunol 32:1958-1968, 2002.
12. Heil F, Ahmad-Nejad P, Hemmi H, Hochrein H, Ampenberger F, Gellert T, Dietrich H, Lipford G, Takeda K, Akira S, et al.: The Toll-like receptor 7 (TLR7)Yspecific stimulus loxoribine uncovers a strong relationship within the TLR7, 8 and 9 subfamily. Eur J Immunol 33:2987-2997, 2003.
13. Latz E, Schoenemeyer A, Visintin A, Fitzgerald KA, Monks BG, Knetter CF, Lien E, Nilsen NJ, Espevik T, Golenbock DT: TLR9 signals after translocating from the ER to CpG DNA in the lysosome. Nat Immunol 5:190-198, 2004.
14. Takeuchi O, Kawai T, Muhlradt PF, Morr M, Radolf JD, Zychlinsky A, Takeda K, Akira S: Discrimination of bacterial lipoproteins by Toll-like receptor 6. Int Immunol 13:933-940, 2001.
15. Takeuchi O, Sato S, Horiuchi T, Hoshino K, Takeda K, Dong Z, Modlin RL, Akira S: Cutting edge: role of Toll-like receptor 1 in mediating immune response to microbial lipoproteins. J Immunol 169:10-14, 2002.
16. Saitoh S, Akashi S, Yamada T, Tanimura N, Kobayashi M, Konno K, Matsumoto F, Fukase K, Kusumoto S, Nagai Y, et al.: Lipid A antagonist, lipid IVa, is distinct from lipid A in interaction with Toll-like receptor 4 (TLR4)-MD-2 and ligand-induced TLR4 oligomerization. Int Immunol 16: 961-969, 2004.
17. Latz E, Verma A, Visintin A, Gong M, Sirois CM, Klein DC, Monks BG, McKnight CJ, Lamphier MS, Duprex WP, et al.: Ligand-induced conforma-tional changes allosterically activate Toll-like receptor 9. Nat Immunol 8: 772-779, 2007.
18. O'Neill LA, Bowie AG: The family of five: TIR-domain-containing adaptors in Toll-like receptor signalling. Nat Rev Immunol 7:353-364, 2007.
19. Lord KA, Hoffman-Liebermann B, Liebermann DA: Nucleotide sequence and expression of a cDNA encoding MyD88, a novel myeloid differentiation primary response gene induced by IL6. Oncogene 5:1095-1097, 1990.
20. Hultmark D: Macrophage differentiation marker MyD88 is a member of the Toll/IL-1 receptor family. Biochem Biophys Res Commun 199:144-146, 1994.
21. Medzhitov R, Preston-Hurlburt P, Kopp E, Stadlen A, Chen C, Ghosh S, Janeway CA Jr: MyD88 is an adaptor protein in the hToll/IL-1 receptor family signaling pathways. Mol Cell 2:253-258, 1998.
22. Horng T, Medzhitov R: Drosophila MyD88 is an adapter in the Toll signaling pathway. Proc Natl Acad Sci USA 98:12654-12658, 2001.
23. Akira S, Takeda K: Toll-like receptor signalling. Nat Rev Immunol 4:499-511, 2004.
24. Janssens S, Beyaert R: Functional diversity and regulation of different interleukin-1 receptorYassociated kinase (IRAK) family members. Mol Cell 11:293-302, 2003.
25. Takeuchi O, Kaufmann A, Grote K, Kawai T, Hoshino K, Morr M, Muhlradt PF, Akira S: Cutting edge: preferentially the R-stereoisomer of the myco-plasmal lipopeptide macrophage-activating lipopeptide-2 activates immune cells through a Toll-like receptor 2-and MyD88-dependent signaling pathway. J Immunol 164:554-557, 2000.
26. Takeuchi O, Takeda K, Hoshino K, Adachi O, Ogawa T, Akira S: Cellular responses to bacterial cell wall components are mediated through MyD88-dependent signaling cascades. Int Immunol 12:113-117, 2000.
27. Kawai T, Adachi O, Ogawa T, Takeda K, Akira S: Unresponsiveness of MyD88-deficient mice to endotoxin. Immunity 11:115-122, 1999.
28. Li X, Commane M, Burns C, Vithalani K, Cao Z, Stark GR: Mutant cells that do not respond to interleukin-1 (IL-1) reveal a novel role for IL-1 receptorYassociated kinase. Mol Cell Biol 19:4643-4652, 1999.
29. Kim TW, Staschke K, Bulek K, Yao J, Peters K, Oh KH, Vandenburg Y, Xiao H, Qian W, Hamilton T, et al.: A critical role for IRAK4 kinase activity in Toll-like receptorYmediated innate immunity. J Exp Med 204: 1025-1036, 2007.
30. Suzuki N, Suzuki S, Duncan GS, Millar DG, Wada T, Mirtsos C, Takada H, Wakeham A, Itie A, Li S, et al.: Severe impairment of interleukin-1 and Tolllike receptor signalling in mice lacking IRAK-4. Nature 416:750-756, 2002.
31. Kanakaraj P, Ngo K, Wu Y, Angulo A, Ghazal P, Harris CA, Siekierka JJ, Peterson PA, Fung-Leung WP: Defective interleukin (IL)-18Ymediated natural killer and T helper cell type 1 responses in IL-1 receptorYassociated kinase (IRAK)Ydeficient mice. J Exp Med 189:1129-1138, 1999.
32. Thomas JA, Allen JL, Tsen M, Dubnicoff T, Danao J, Liao XC, Cao Z, Wasserman SA: Impaired cytokine signaling in mice lacking the IL-1 receptorY associated kinase. J Immunol 163:978-984, 1999.
33. Meylan E, Tschopp J: IRAK2 takes its place in TLR signaling. Nat Immunol 9:581-582, 2008.
34. Li S, Strelow A, Fontana EJ, Wesche H: IRAK-4: a novel member of the IRAK family with the properties of an IRAK-kinase. Proc Natl Acad Sci USA 99:5567-5572, 2002.
35. Muzio M, Natoli G, Saccani S, Levrero M, Mantovani A: The human toll signaling pathway: divergence of nuclear factor kappa B and JNK/SAPK activation upstream of tumor necrosis factor receptorYassociated factor 6 (TRAF6). J Exp Med 187:2097-2101, 1998.
36. Kawagoe T, Sato S, Matsushita K, Kato H, Matsui K, Kumagai Y, Saitoh T, Kawai T, Takeuchi O, Akira S: Sequential control of Toll-like receptorY dependent responses by IRAK1 and IRAK2. Nat Immunol 9:684-691, 2008.
37. Jiang Z, Ninomiya-Tsuji J, Qian Y, Matsumoto K, Li X: Interleukin-1 (IL-1) receptorYassociated kinaseYdependent IL-1Yinduced signaling complexes phosphorylate TAK1 and TAB2 at the plasma membrane and activate TAK1 in the cytosol. Mol Cell Biol 22:7158-7167, 2002.
38. Takaesu G, Kishida S, Hiyama A, Yamaguchi K, Shibuya H, Irie K, Ninomiya-Tsuji J, Matsumoto K: TAB2, a novel adaptor protein, mediates activation of TAK1 MAPKKK by linking TAK1 to TRAF6 in the IL-1 signal transduction pathway. Mol Cell 5:649-658, 2000.
39. Takaesu G, Surabhi RM, Park KJ, Ninomiya-Tsuji J, Matsumoto K, Gaynor RB: TAK1 is critical for IkappaB kinaseYmediated activation of the NF-kappaB pathway. J Mol Biol 326:105-115, 2003.
40. Chen ZJ: Ubiquitin signalling in the NF-kappaB pathway. Nat Cell Biol 7:758-765, 2005.
41. Kobayashi K, Hernandez LD, Galan JE, Janeway CA Jr, Medzhitov R, Flavell RA: IRAK-M is a negative regulator of Toll-like receptor signaling. Cell 110:191-202, 2002.
42. Wesche H, Gao X, Li X, Kirschning CJ, Stark GR, Cao Z: IRAK-M is a novel member of the Pelle/interleukin-1 receptorYassociated kinase (IRAK) family. J Biol Chem 274:19403-19410, 1999.
43. Horng T, Barton GM, Medzhitov R: TIRAP: an adapter molecule in the Toll signaling pathway. Nat Immunol 2:835-841, 2001.
44. Fitzgerald KA, Palsson-McDermott EM, Bowie AG, Jefferies CA, Mansell AS, Brady G, Brint E, Dunne A, Gray P, Harte MT, et al.: Mal (MyD88-adapter-like) is required for Toll-like receptor-4 signal transduction. Nature 413:78-83, 2001.
45. Yamamoto M, Sato S, Hemmi H, Sanjo H, Uematsu S, Kaisho T, Hoshino K, Takeuchi O, Kobayashi M, Fujita T, et al.: Essential role for TIRAP in activation of the signalling cascade shared by TLR2 and TLR4. Nature 420:324-329, 2002.
46. Kagan JC, Medzhitov R: Phosphoinositide-mediated adaptor recruitment controls Toll-like receptor signaling. Cell 125:943-955, 2006.
47. Mansell A, Brint E, Gould JA, O'Neill LA, Hertzog PJ: Mal interacts with tumor necrosis factor receptorYassociated factor (TRAF)-6 to mediate NF-kappaB activation by toll-like receptor (TLR)-2 and TLR4. J Biol Chem 279:37227-37230, 2004.
48. Gray P, Dunne A, Brikos C, Jefferies CA, Doyle SL, O'Neill LA: MyD88 adapter-like (Mal) is phosphorylated by Bruton's tyrosine kinase during TLR2 and TLR4 signal transduction. J Biol Chem 281:10489-10495, 2006.
49. Mansell A, Smith R, Doyle SL, Gray P, Fenner JE, Crack PJ, Nicholson SE, Hilton DJ, O'Neill LA, Hertzog PJ: Suppressor of cytokine signaling 1 negatively regulates Toll-like receptor signaling by mediating Mal degradation. Nat Immunol 7:148-155, 2006.
50. Kawai T, Takeuchi O, Fujita T, Inoue J, Muhlradt PF, Sato S, Hoshino K, Akira S: Lipopolysaccharide stimulates the MyD88-independent pathway and results in activation of IFN-regulatory factor 3 and the expression of a subset of lipopolysaccharide-inducible genes. J Immunol 167:5887-5894, 2001.
51. Yamamoto M, Sato S, Mori K, Hoshino K, Takeuchi O, Takeda K, Akira S: Cutting edge: a novel Toll/IL-1 receptor domainYcontaining adapter that preferentially activates the IFN-beta promoter in the Toll-like receptor signaling. J Immunol 169:6668-6672, 2002.
52. Yamamoto M, Sato S, Hemmi H, Hoshino K, Kaisho T, Sanjo H, Takeuchi O, Sugiyama M, Okabe M, Takeda K, et al.: Role of adaptor TRIF in the MyD88-independent toll-like receptor signaling pathway. Science 301: 640-643, 2003. (Pubitemid 36927946)
53. Hoebe K, Du X, Georgel P, Janssen E, Tabeta K, Kim SO, Goode J, Lin P, Mann N, Mudd S, et al.: Identification of Lps2 as a key transducer of MyD88-independent TIR signalling. Nature 424:743-748, 2003.
54. Toshchakov V, Jones BW, Perera PY, Thomas K, Cody MJ, Zhang S, Williams BR, Major J, Hamilton TA, Fenton MJ, et al.: TLR4, but not TLR2 mediates IFN-betaYinduced STAT1alpha/beta-dependent gene expression in macrophages. Nat Immunol 3:392-398, 2002.
55. Covert MW, Leung TH, Gaston JE, Baltimore D: Achieving stability of lipopolysaccharide-induced NF-kappaB activation. Science 309:1854-1857, 2005.
56. Oshiumi H, Matsumoto M, Funami K, Akazawa T, Seya T: TICAM-1, an adaptor molecule that participates in Toll-like receptor 3Ymediated interferon-beta induction. Nat Immunol 4:161-167, 2003.
57. Oshiumi H, Sasai M, Shida K, Fujita T, Matsumoto M, Seya T: TIR-containing adapter molecule (TICAM)-2, a bridging adapter recruiting to tolllike receptor 4 TICAM-1 that induces interferon-beta. J Biol Chem 278: 49751-49762, 2003.
58. Rowe DC, McGettrick AF, Latz E, Monks BG, Gay NJ, Yamamoto M, Akira S, O'Neill LA, Fitzgerald KA, Golenbock DT: The myristoylation of TRIF-related adaptor molecule is essential for Toll-like receptor 4 signal transduction. Proc Natl Acad Sci USA 103:6299-6304, 2006.
59. Fitzgerald KA, Chen ZJ: Sorting out Toll signals. Cell 125:834-836, 2006.
60. Yamamoto M, Sato S, Hemmi H, Uematsu S, Hoshino K, Kaisho T, Takeuchi O, Takeda K, Akira S: TRAM is specifically involved in the Toll-like receptor 4Ymediated MyD88-independent signaling pathway. Nat Immunol 4: 1144-1150, 2003. (Pubitemid 37428043)
61. Watts C: Location, location, location: identifying the neighborhoods of LPS signaling. Nat Immunol 9:343-345, 2008.
62. Mink M, Fogelgren B, Olszewski K, Maroy P, Csiszar K: A novel human gene (SARM) at chromosome 17q11 encodes a protein with a SAM motif and structural similarity to Armadillo/beta-catenin that is conserved in mouse, Drosophila, and Caenorhabditis elegans. Genomics 74:234-244, 2001.
63. Couillault C, Pujol N, Reboul J, Sabatier L, Guichou JF, Kohara Y, Ewbank JJ: TLR-independent control of innate immunity in Caenorhabditis elegans by the TIR domain adaptor protein TIR-1, an ortholog of human SARM. Nat Immunol 5:488-494, 2004.
64. Liberati NT, Fitzgerald KA, Kim DH, Feinbaum R, Golenbock DT, Ausubel FM: Requirement for a conserved Toll/interleukin-1 resistance domain protein in the Caenorhabditis elegans immune response. Proc Natl Acad Sci USA 101:6593-6598, 2004.
65. Carty M, Goodbody R, Schroder M, Stack J, Moynagh PN, Bowie AG: The human adaptor SARM negatively regulates adaptor protein TRIFYdependent Toll-like receptor signaling. Nat Immunol 7:1074-1081, 2006.
66. Ishikawa H, Barber GN: STING is an endoplasmic reticulum adaptor that facilitates innate immune signalling. Nature 455:674-678, 2008.
67. Tabeta K, Hoebe K, Janssen EM, Du X, Georgel P, Crozat K, Mudd S, Mann N, Sovath S, Goode J, et al.: The Unc93b1 mutation 3d disrupts exogenous antigen presentation and signaling via Toll-like receptors 3, 7 and 9. Nat Immunol 7:156-164, 2006.
68. Jefferies CA, Doyle S, Brunner C, Dunne A, Brint E, Wietek C, Walch E, Wirth T, O'Neill LA: Bruton's tyrosine kinase is a Toll/interleukin-1 receptor domainYbinding protein that participates in nuclear factor kappaB activation by Toll-like receptor 4. J Biol Chem 278:26258-26264, 2003.
69. Bajpai UD, Zhang K, Teutsch M, Sen R, Wortis HH: Bruton's tyrosine kinase links the B cell receptor to nuclear factor kappaB activation. J Exp Med 191:1735-1744, 2000.
70. Petro JB, Rahman SM, Ballard DW, Khan WN: Bruton's tyrosine kinase is required for activation of IkappaB kinase and nuclear factor kappaB in response to B cell receptor engagement. J Exp Med 191:1745-1754, 2000.
71. Horwood NJ, Page TH, McDaid JP, Palmer CD, Campbell J, Mahon T, Brennan FM, Webster D, Foxwell BMJ: Bruton's tyrosine kinase is required for TLR2 and TLR4-induced TNF, but not IL-6, production. J Immunol 176:3635-3641, 2006.
72. Castrillo A, Pennington DJ, Otto F, Parker PJ, Owen MJ, Bosca L: Protein kinase Cepsilon is required for macrophage activation and defense against bacterial infection. J Exp Med 194:1231-1242, 2001.
73. Wald D, Qin J, Zhao Z, Qian Y, Naramura M, Tian L, Towne J, Sims JE, Stark GR, Li X: SIGIRR, a negative regulator of Toll-like receptorYinterleukin 1 receptor signaling. Nat Immunol 4:920-927, 2003.
74. Thomassen E, Renshaw BR, Sims JE: Identification and characterization of SIGIRR, a molecule representing a novel subtype of the IL-1R superfamily. Cytokine 11:389-399, 1999.
75. O'Neill LA: SIGIRR puts the brakes on Toll-like receptors. Nat Immunol 4:823-824, 2003.
76. Brint EK, Xu D, Liu H, Dunne A, McKenzie AN, O'Neill LA, Liew FY: ST2 is an inhibitor of interleukin 1 receptor and Toll-like receptor 4 signaling and maintains endotoxin tolerance. Nat Immunol 5:373-379, 2004.
77. Burns K, Janssens S, Brissoni B, Olivos N, Beyaert R, Tschopp J: Inhibition of interleukin 1 receptor/Toll-like receptor signaling through the alternatively spliced, short form of MyD88 is due to its failure to recruit IRAK-4. J Exp Med 197:263-268, 2003.
78. Janssens S, Burns K, Vercammen E, Tschopp J, Beyaert R: MyD88S, a splice variant of MyD88, differentially modulates NF-kappaBY and AP-1Ydependent gene expression. FEBS Lett 548:103-107, 2003.
79. Burns K, Clatworthy J, Martin L, Martinon F, Plumpton C, Maschera B, Lewis A, Ray K, Tschopp J, Volpe F: Tollip, a new component of the IL-1RI pathway, links IRAK to the IL-1 receptor. Nat Cell Biol 2:346-351, 2000.
80. Zhang G, Ghosh S: Negative regulation of Toll-like receptorYmediated signaling by Tollip. J Biol Chem 277:7059-7065, 2002.
81. Wang Y, Tang Y, Teng L, Wu Y, Zhao X, Pei G: Association of beta-arrestin and TRAF6 negatively regulates Toll-like receptorYinterleukin 1 receptor signaling. Nat Immunol 7:139-147, 2006.
82. Khursigara G, Orlinick JR, Chao MV: Association of the p75 neurotrophin receptor with TRAF6. J Biol Chem 274:2597-2600, 1999.
83. Choi KC, Lee YS, Lim S, Choi HK, Lee CH, Lee EK, Hong S, Kim IH, Kim SJ, Park SH: Smad6 negatively regulates interleukin 1-receptorYTolllike receptor signaling through direct interaction with the adaptor Pellino-1. Nat Immunol 7:1057-1065, 2006.
84. Ananieva O, Darragh J, Johansen C, Carr JM, McIlrath J, Park JM, Wingate A, Monk CE, Toth R, Santos SG, et al.: The kinases MSK1 and MSK2 act as negative regulators of Toll-like receptor signaling. Nat Immunol 9:1028-1036, 2008.
85. Darragh J, Soloaga A, Beardmore VA, Wingate AD, Wiggin GR, Peggie M, Arthur JS: MSKs are required for the transcription of the nuclear orphan receptors Nur77, Nurr1 and Nor1 downstream of MAPK signalling. Biochem J 390:749-759, 2005.
86. Rothlin CV, Ghosh S, Zuniga EI, Oldstone MB, Lemke G: TAM receptors are pleiotropic inhibitors of the innate immune response. Cell 131:1124-1136, 2007.
87. Chuang TH, Ulevitch RJ: Triad3A, an E3 ubiquitin-protein ligase regulating Toll-like receptors. Nat Immunol 5:495-502, 2004.
88. Gilchrist M, Thorsson V, Li B, Rust AG, Korb M, Roach JC, Kennedy K, Hai T, Bolouri H, Aderem A: Systems biology approaches identify ATF3 as a negative regulator of Toll-like receptor 4. Nature 441:173-178, 2006.
89. Brikos C, O'Neill LA: Signalling of toll-like receptors. Handb Exp Pharmacol 183:21-50, 2008.
90. O'Neill LA: When signaling pathways collide: positive and negative regulation of toll-like receptor signal transduction. Immunity 29:12-20, 2008.
91. Breslin JW, Wu MH, Guo M, Reynoso R, Yuan SY: Toll-like receptor 4 contributes to microvascular inflammation and barrier dysfunction in thermal injury. Shock 29:349-355, 2008.
92. Bruns B, Maass D, Barber R, Horton J, Carlson D: Alterations in the cardiac inflammatory response to burn trauma in mice lacking a functional Toll-like receptor 4 gene. Shock 30:740-746, 2008.
93. Cartwright N, McMaster SK, Sorrentino R, Paul-Clark M, Sriskandan S, Ryffel B, Quesniaux VFJ, Evans TW, Mitchell JA: Elucidation of Toll-like receptor and adapter protein signaling in vascular dysfunction induced by gram-positive Staphylococcus aureus or gram-negative Escherichia coli. Shock 27:40-47, 2007.
94. Hadley JS, Wang JE, Michaels LC, Dempsey CM, Foster SJ, Thiemermann C, Hinds CJ: Alterations in inflammatory capacity and TLR expression on mono-cytes and neutrophils after cardiopulmonary bypass. Shock 27:466-473, 2007.
95. Hua F, Ha T, Ma J, Li Y, Kelley J, Gao X, Browder IW, Kao RL, Williams DL, Li C: Protection against myocardial ischemia/reperfusion injury in TLR4-deficient mice is mediated through a phosphoinositide 3-kinaseYdependent mechanism. J Immunol 178:7317-7324, 2007.
96. Kaczorowski DJ, Nakao A, Vallabhaneni R, Mollen KP, Sugimoto R, Kohmoto J, Zuckerbraun BS, McCurry KR, Billiar TR: Mechanisms of Toll-like receptor 4 (TLR4)Ymediated inflammation after cold ischemia/reperfusion in the heart. Transplantation 87:1455-1463, 2009.
97. Mollen KP, Anand RJ, Tsung A, Prince JM, Levy RM, Billiar TR: Emerging paradigm: Toll-like receptor 4-sentinel for the detection of tissue damage. Shock 26:430-437, 2006.
98. Pearl-Yafe M, Fabian I, Halperin D, Flatau E, Werber S, Shalit I: Interferon-[gamma] and bacterial lipopolysaccharide act synergistically on human neutrophils enhancing interleukin-8, interleukin-1[beta], tumor necrosis factor-[alpha], and interleukin-12 p70 secretion and phagocytosis via upre-gulation of toll-like receptor 4. Shock 27:226-231, 2007.
99. Sharma AC: Sepsis-induced myocardial dysfunction. Shock 25:14-15, 2006.
100. Tsujimoto H, Ono S, Efron PA, Scumpia PO, Moldawer LL, Mochizuki H: Role of Toll-like receptors in the development of sepsis. Shock 29:315-321 2008.
101. Tsung A, McCoy SL, Klune JR, Geller DA, Billiar TR, Hefeneider SH: A novel inhibitory peptide of toll-like receptor signaling limits lipopolysaccharide-induced production of inflammatory mediators and enhances survival in mice. Shock 27:364-369, 2007.
102. van der Heijden M, Versteilen AMG, Sipkema P, van Nieuw Amerongen GP, Musters RJP, Groeneveld ABJ: Rho-kinase inhibition attenuates endothelial cell apoptosis following simulated ischemia and reperfusion by Akt phos-phorylation. Shock 26:15, 2006.
103. Fredrikson GN, Soderberg I, Lindholm M, Dimayuga P, Chyu K-Y, Shah PK, Nilsson J: Inhibition of atherosclerosis in ApoE-null mice by immunization with ApoB-100 peptide sequences. Arterioscler Thromb Vasc Biol 23: 879-884, 2003.
104. Edfeldt K, Swedenborg J, Hansson GK, Yan Z-Q: Expression of Toll-like receptors in human atherosclerotic lesions: a possible pathway for plaque activation. Circulation 105:1158-1161, 2002.
105. Hollestelle SCG, de Vries MR, van Keulen JK, Schoneveld AH, Vink A, Strijder CF, van Middelaar BJ, Pasterkamp G, Quax PHA, de Kleijn DPV: Toll-like receptor 4 is involved in outward arterial remodeling. Circulation 109:393-398, 2004.
106. Michelsen KS, Doherty TM, Shah PK, Arditi M: TLR signaling: an emerging bridge from innate immunity to atherogenesis. J Immunol 173:5901-5907, 2004.
107. Arumugam TV, Okun E, Tang SC, Thundyil J, Taylor SM, Woodruff TM: Toll-like receptors in ischemia-reperfusion injury. Shock 32:4-16, 2009.
108. Khandoga AG, Khandoga A, Anders H-J, Krombach F: Postischemic vascular permeability requires both TLR-2 and TLR-4, but only TLR-2 mediates the transendothelial migration of leukocytes. Shock 31:593-599, 2009.
109. Hoth JJ, Wells JD, Brownlee NA, Hiltbold EM, Meredith JW, McCall CE, Yoza BK: Toll-like receptor 4-dependent responses to lung injury in a murine model of pulmonary contusion. Shock 31:376-381, 2009.
110. Patel TA, Belcher E, Warner TD, Harding SNE, Mitchell JA: Identification and characterization of a dysfunctional cardiac myocyte phenotype: role of bacteria, Toll-like receptors, and endothelin. Shock 28:434-440, 2007.
111. Feinman R, Deitch EA, Aris V, Chu HB, Abungu B, Caputo FJ, Galante A, Xu D, Lu Q, Colorado I, et al.: Molecular signatures of trauma-hemorrhagic shock-induced lung injury: hemorrhage-and injury-associated genes. Shock 28:360-368. 2007.
112. Fan J, Leaphart CL, Cavallo J, Anand RJ, Li J, Hackam DJ: Epidermal growth factor (EGF) attenuates LPS-mediated signaling in enterocytes through reduced expression of toll like receptor 4 during endotoxemic stress. Shock 25:19, 2006.
113. Oyama J, Blais C Jr, Liu X, Pu M, Kobzik L, Kelly RA, Bourcier T: Reduced myocardial ischemia-reperfusion injury in toll-like receptor 4Ydeficient mice. Circulation 109:784-789, 2004.
114. Chong AJ, Shimamoto A, Hampton CR, Takayama H, Spring DJ, Rothnie CL, Yada M, Pohlman TH, Verrier ED: Toll-like receptor 4 mediates ischemia/reperfusion injury of the heart. J Thorac Cardiovasc Surg 128:170-179, 2004.
115. Zhu X, Zhao H, Graveline AR, Buys ES, Schmidt U, Bloch KD, Rosenzweig A, Chao W: MyD88 and NOS2 are essential for toll-like receptor 4Ymediated survival effect in cardiomyocytes. Am J Physiol Heart Circ Physiol 291: H1900-H1909, 2006.
116. Chao W: Toll-like receptor signaling: a critical modulator of cell survival and ischemic injury in the heart. Am J Physiol Heart Circ Physiol 296:H1-H12, 2009.
117. Satoh M, Shimoda Y, Maesawa C, Akatsu T, Ishikawa Y, Minami Y, Hiramori K, Nakamura M: Activated toll-like receptor 4 in monocytes is associated with heart failure after acute myocardial infarction. Int J Cardiol 109:226-234, 2006.
118. Cha J, Wang Z, Ao L, Zou N, Dinarello CA, Banerjee A, Fullerton DA, Meng X: Cytokines link toll-like receptor 4 signaling to cardiac dysfunction after global myocardial ischemia. Ann Thorac Surg 85:1678-1685, 2008.
119. Favre J, Musette P, Douin-Echinard V, Laude K, Henry JP, Arnal JF, Thuillez C, Richard V: Toll-like receptors 2Ydeficient mice are protected against postischemic coronary endothelial dysfunction. Arterioscler Thromb Vasc Biol 27:1064-1071, 2007.
120. Sakata Y, Dong JW, Vallejo JG, Huang CH, Baker JS, Tracey KJ, Tacheuchi O, Akira S, Mann DL: Toll-like receptor 2 modulates left ventricular function following ischemia-reperfusion injury. Am J Physiol Heart Circ Physiol 292:H503-H509, 2007.
121. Shishido T, Nozaki N, Yamaguchi S, Shibata Y, Nitobe J, Miyamoto T, Takahashi H, Arimoto T, Maeda K, Yamakawa M, et al.: Toll-like receptor-2 modulates ventricular remodeling after myocardial infarction. Circulation 108:2905-2910, 2003.
122. Boyd JH, Mathur S, Wang Y, Bateman RM, Walley KR: Toll-like receptor stimulation in cardiomyocytes decreases contractility and initiates an NF-kappaB dependent inflammatory response. Cardiovasc Res 72:384-393, 2006.
123. Hua F, Ha T, Ma J, Gao X, Kelley J, Williams DL, Browder IW, Kao RL, Li C: Blocking the MyD88-dependent pathway protects the myocardium from ischemia/reperfusion injury in rat hearts. Biochem Biophys Res Com-mun 338:1118-1125, 2005.
124. Morishita R, Sugimoto T, Aoki M, Kida I, Tomita N, Moriguchi A, Maeda K, Sawa Y, Kaneda Y, Higaki J, et al.: In vivo transfection of cis element Bdecoy against nuclear factorYkappaB binding site prevents myocardial infarction. Nat Med 3:894-899, 1997.
125. Moss NC, Stansfield WE, Willis MS, Tang RH, Selzman CH: IKKbeta inhibition attenuates myocardial injury and dysfunction following acute ischemia-reperfusion injury. Am J Physiol Heart Circ Physiol 293:H2248-H2253, 2007.
126. Meili-Butz S, Niermann T, Fasler-Kan E, Barbosa V, Butz N, John D, Brink M, Buser PT, Zaugg CE: Dimethyl fumarate, a small molecule drug for psoriasis, inhibits nuclear factor-kappaB and reduces myocardial infarct size in rats. Eur J Pharmacol 586:251-258, 2008.
127. Onai Y, Suzuki J, Kakuta T, Maejima Y, Haraguchi G, Fukasawa H, Muto S, Itai A, Isobe M: Inhibition of IkappaB phosphorylation in cardiomyocytes attenuates myocardial ischemia/reperfusion injury. Cardiovasc Res 63:51-59, 2004.
128. Frantz S, Tillmanns J, Kuhlencordt PJ, Schmidt I, Adamek A, Dienesch C, Thum T, Gerondakis S, Ertl G, Bauersachs J: Tissue-specific effects of the nuclear factor kappaB subunit p50 on myocardial ischemia-reperfusion injury. Am J Pathol 171:507-512, 2007.
129. Siebenlist U, Franzoso G, Brown K: Structure, regulation and function of NF-kappa B. Annu Rev Cell Biol 10:405-455, 1994.
130. Shigeoka AA, Holscher TD, King AJ, Hall FW, Kiosses WB, Tobias PS, Mackman N, McKay DB: TLR2 is constitutively expressed within the kidney and participates in ischemic renal injury through both MyD88-dependent and-independent pathways. J Immunol 178:6252-6258, 2007.
131. Yang QW, Li JC, Lu FL, Wen AQ, Xiang J, Zhang LL, Huang ZY, Wang JZ: Upregulated expression of toll-like receptor 4 in monocytes correlates with severity of acute cerebral infarction. J Cereb Blood Flow Metab 28: 1588-1596, 2008.
132. Du J, An J, Wei N, Guan T, Pritchard KA Jr, Shi Y: Increased resistance to LPS-induced myocardial dysfunction in the Brown Norway rats vs. Dahl S rats: roles of inflammatory cytokines and NFkappaB pathway. Shock 33:332-336, 2010.
133. Kin H, Wang N-P, Mykytenko J, Reeves J, Deneve J, Jiang R, Zatta AJ, Guyton RA, Vinten-Johansen J, Zhao ZQ, et al.: Inhibition of myocardial apoptosis by postconditioning is associated with attenuation of oxidative stress-mediated nuclear factor-kappa B translocation and TNF alpha release. Shock 29:761-768, 2008.
134. Nydam TL, Moore EE, McIntyre RC Jr, Wright FL, Gamboni-Robertson F, Eckels PC, Banerjee A: Hypertonic saline attenuates TNF-alphaYinduced NF-kappa B activation in pulmonary epithelial cells. Shock 31:466-472, 2009.
135. Abraham E: The role of NF-kappa B in acute lung injury and pulmonary inflammation. Shock 25:12-13, 2006.
136. Hardiman G, Rock FL, Balasubramanian S, Kastelein RA, Bazan JF: Molecular characterization and modular analysis of human MyD88. Oncogene 13:2467-2475, 1996.
137. Fujio Y, Nguyen T, Wencker D, Kitsis RN, Walsh K: Akt promotes survival of cardiomyocytes in vitro and protects against ischemia-reperfusion injury in mouse heart. Circulation 101:660-667, 2000.
138. Guha M, Mackman N: The phosphatidylinositol 3-kinase-Akt pathway limits lipopolysaccharide activation of signaling pathways and expression of inflammatory mediators in human monocytic cells. J Biol Chem 277: 32124-32132, 2002.
139. Williams DL, Li C, Ha T, Ozment-Skelton T, Kalbfleisch JH, Preiszner J, Brooks L, Breuel K, Schweitzer JB: Modulation of the phosphoinositide 3-kinase pathway alters innate resistance to polymicrobial sepsis. J Immunol 172:449-456, 2004.
140. Mahaffey KW, Granger CB, Nicolau JC, Ruzyllo W, Weaver WD, Theroux P, Hochman JS, Filloon TG, Mojcik CF, Todaro TG, et al.: Effect of pex-elizumab, an anti-C5 complement antibody, as adjunctive therapy to fibri-nolysis in acute myocardial infarction: the COMPlement inhibition in myocardial infarction treated with thromboLYtics (COMPLY) trial. Circulation 108:1176-1183, 2003. (Pubitemid 37099984)
141. Roberts R, DeMello V, Sobel BE: Deleterious effects of methylprednisolone in patients with myocardial infarction. Circulation 53:I204-I206, 1976.